SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-21-025045
Filing Date
2021-06-21
Accepted
2021-06-21 17:35:15
Documents
1
Period of Report
2021-06-18

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4075
  Complete submission text file 0000899243-21-025045.txt   5474
Mailing Address C/O INTERCEPT PHARMACEUTICALS, INC. 18 DESBROSSES STREET NEW YORK NY 10013
Business Address
Duncan Barbara Gayle (Reporting) CIK: 0001353128 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39661 | Film No.: 211032149

Mailing Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110
Business Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Issuer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences